<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02695004</url>
  </required_header>
  <id_info>
    <org_study_id>DKF-310-P1</org_study_id>
    <nct_id>NCT02695004</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics of DKF-310 Intramuscular Injection in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dongkook Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dongkook Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate safety, tolerability and PK of DKF-310 IM injection in healthy
      male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>1056h</time_frame>
    <description>0, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 240, 312, 360, 408, 432, 456, 480, 504, 528, 552, 600, 720, 816, 888, 960, 1056h</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>1056h</time_frame>
    <description>0, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 240, 312, 360, 408, 432, 456, 480, 504, 528, 552, 600, 720, 816, 888, 960, 1056h</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Donepezil 35 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil 35 mg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Donepezil 70 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil 70 mg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Donepezil140 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil 140 mg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Donepezil 210 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil 210 mg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Donepezil 280 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil 280 mg or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DKF-310</intervention_name>
    <arm_group_label>Donepezil 35 mg</arm_group_label>
    <arm_group_label>Donepezil 70 mg</arm_group_label>
    <arm_group_label>Donepezil140 mg</arm_group_label>
    <arm_group_label>Donepezil 210 mg</arm_group_label>
    <arm_group_label>Donepezil 280 mg</arm_group_label>
    <other_name>Donepezil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Donepezil 35 mg</arm_group_label>
    <arm_group_label>Donepezil 70 mg</arm_group_label>
    <arm_group_label>Donepezil140 mg</arm_group_label>
    <arm_group_label>Donepezil 210 mg</arm_group_label>
    <arm_group_label>Donepezil 280 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men aged 19 to 50 years

          -  Body weight 55 to 90 kg and BMI 18.0 to 27.0

          -  Voluntarily signed the informed consent form

          -  Eligible according to the screening test results

          -  Available to follow up after drop-out

        Exclusion Criteria:

          -  Clinically significant disorders or a medical history of hepatic, renal, neurological,
             respiratory, endocrine, hemato-oncologic, cardiovascular, urological and psychiatric
             diseases

          -  Hypersensitivity to donepezil, piperidine derivatives and other drugs

          -  SBP &lt;100 mmHg or &gt;150 mmHg, or DBP &lt;60 mmHg or &gt;100 mmHg

          -  Skin and muscle disorders or history of surgery at the injection site

          -  AST or ALT &gt;1.5xULN; QT/QTcB interval &gt;450 ms

          -  History or positive result of drug abuse

          -  Prescribed drugs or herbal medicines within 2 weeks, over-the-counter drugs or
             vitamins within 1 week

          -  Participated in other clinical trials within 3 months

          -  Donated whole blood within 2 months or apheresis within 1 month, or transfusion within
             1 month

          -  Alcohol consumption &gt;21 units/week

          -  Smoked &gt;10 cigarettes/day within 3 months

          -  Caffeine-containing foods

          -  Not eligible due to other reasons at the investigator's discretion
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JY Chung</last_name>
    <email>jychung@snubh.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National Univ. Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JY Chung</last_name>
      <email>jychung@snubh.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2016</study_first_submitted>
  <study_first_submitted_qc>February 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2016</study_first_posted>
  <last_update_submitted>February 29, 2016</last_update_submitted>
  <last_update_submitted_qc>February 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

